We have previously reported that both Aurora kinase A and PLK1 are up-modulated and hyper-activated in imatinib-resistant BCR::ABL1 positive CML cells (15). This evidence concerns the gene PLK1 and chronic myelogenous leukemia, BCR-ABL1 positive.